Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06998043 · ClinicalTrials.gov registry record · Phase 2
Study With Phage for CF Subjects With Pseudomonas Lung Infection
A Phase 2 study of Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa Infection, sponsored by BiomX.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 14
- Study locations
NCT06998043: Recruiting Phase 2 study of Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa Infection, sponsored by BiomX.
NCT06998043 is a Phase 2 study of Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa Infection that is actively recruiting participants, run by BiomX. The registered enrollment target is 63 participants, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (54% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06998043, a Phase 2 study of Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa Infection, is actively recruiting participants, sponsored by BiomX.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Primary Outcome
Change from baseline in PsA colony-forming units (CFU) per g of sputum
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL BX004
Study Locations (14)
Florida
- Joe DiMaggio Children's Health - Hollywood
- Central Florida Pulmonary Group - Orlando
- Avanza Medical Center - Pensacola
California
- Stanford University - Palo Alto
- University of California San Francisco - San Francisco
New York
- New York Medical College - Hawthorne
- Northwell Health - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Alaska
- Providence Alaska Medical Center - Anchorage
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- National Jewish Health - Denver
New Jersey
- Rutgers, Robert Wood Johnson Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06998043 shows while recruiting
NCT06998043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06998043 lists 14 locations in 10 states (Florida, California, New York).
Frequently Asked Questions
What is clinical trial NCT06998043 about?
NCT06998043 is a clinical study titled "Study With Phage for CF Subjects With Pseudomonas Lung Infection". The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background ...
What is the current status of trial NCT06998043?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2025-07-02. Estimated completion is 2026-09.
What conditions does trial NCT06998043 study?
This clinical trial studies the following conditions: Cystic Fibrosis (CF), Chronic Pseudomonas Aeruginosa Infection.
What interventions are being tested in trial NCT06998043?
The interventions under investigation include: Placebo (OTHER), BX004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06998043?
This trial is sponsored by BiomX, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06998043 being conducted?
This trial has 14 study locations across Alabama, Alaska, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis (CF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06998043's enrollment target sits among peer trials
63 10th of 14 higher than 5 of 14 other Cystic Fibrosis (CF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis (CF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
COMPLETED · Phase 2
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
RECRUITING · Phase 3
-
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI